By disrupting HSP90 function, celastrol promotes the degradation of BCR-ABL, including the imatinib-resistant T315I mutant, leading to apoptosis in CML cells [106]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.